AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Briefs

Published November 9, 2026

J&J Backs Delix with $100M for Psychedelic Drug - Briefs Finance

Read the full story at Briefs

Johnson & Johnson leads $100 million bet on Delix's non-hallucinogenic psychedelics · The deal and who backed it · What Delix is building · Timelines,.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics